STOCK TITAN

Keros Therapeutics approves stock buyback of up to $5M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Keros Therapeutics, Inc. (KROS) approved a share repurchase program for up to $5 million of its common stock after receiving a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under the elritercept license agreement. The milestone followed dosing of the first patient in the ELRiSE MF clinical trial. Management is authorized to repurchase shares from time to time in the open market and/or by other means in accordance with applicable securities laws. The program may be modified, suspended or discontinued at any time and does not require Keros to repurchase shares.

Keros reported $259.5 million in cash and cash equivalents as of September 30, 2026. Based on current operating plans, it anticipates that cash and cash equivalents, after giving effect to the November 2026 milestone payment and the repurchase program, will fund operating expenses and capital expenditure requirements into 2029. Repurchase timing and amounts will depend on factors including the share price, market and economic conditions, and contractual limitations.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Share repurchase authorization Up to $5 million Board-approved program for the company's common stock
Development milestone payment $20 million Received from Takeda under the elritercept license agreement in November 2026
Cash and cash equivalents $259.5 million As of September 30, 2026
Operating-expense and capital-expenditure funding outlook Into 2029 Company anticipation based on current operating plans, after giving effect to the milestone payment and repurchase program
development milestone payment financial
"a $20 million development milestone payment"
A development milestone payment is a one-time sum paid when a company reaches a predefined step in a research or product development deal, such as completing a clinical trial phase or achieving a regulatory approval milestone. Like a reward for passing a checkpoint on a long journey, these payments can boost revenue and cash flow suddenly and reduce development risk for the payer, so investors watch them as indicators of progress, future income potential, and changes in valuation.
share repurchase program financial
"approved a new share repurchase program"
A share repurchase program is when a company buys back its own shares from the marketplace. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's prospects. For investors, it often suggests that the company believes its stock is undervalued or that it has extra cash to return to shareholders.
capital expenditure requirements financial
"fund its operating expenses and capital expenditure requirements into 2029"
ELRiSE MF clinical trial medical
"dosing of the first patient in the ELRiSE MF clinical trial"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much has KROS authorized for share repurchases?

Keros’ board approved a program for up to $5 million of common stock. The approval followed receipt of a $20 million development milestone payment under the elritercept license agreement with Takeda Pharmaceuticals U.S.A., Inc.

How long does KROS expect its cash to fund operations?

Keros anticipates that cash and cash equivalents will fund operating expenses and capital expenditure requirements into 2029. The company reported $259.5 million in cash and cash equivalents as of September 30, 2026, and based its outlook on current operating plans after giving effect to the milestone payment and repurchase program.

Does KROS have to repurchase shares under the program?

No. The program does not obligate Keros to repurchase any dollar amount or number of shares, and it may be modified, suspended or discontinued at any time.

How may Keros conduct repurchases under the program?

Management may repurchase shares from time to time in the open market and/or by other means in accordance with applicable state and federal securities laws. Timing and amounts depend on factors including the common stock’s market price, general market and economic conditions, and contractual limitations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001664710FALSE00016647102026-11-162026-11-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2026
 
Keros Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware001-3926481-1173868
(state or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
1050 Waltham Street, Suite 302
Lexington, Massachusetts
02421
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 314-6297
 
Not applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
 
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 



 
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading
Symbol
Name of each exchange
on which registered
Common Stock, $0.0001 par value per shareKROSThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 



Item 8.01 Other Events.

Share Repurchase Program

On November 16, 2026, Keros Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the board of directors of the Company has approved a new stock repurchase program for up to $5 million of the Company’s common stock (the “Stock Repurchase”) following receipt of a $20 million development milestone payment under the license agreement with Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) in November 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

As of September 30, 2026, the Company had cash and cash equivalents of $259.5 million. Based on its current operating plans, the Company anticipates that its cash and cash equivalents as of September 30, 2026, after giving effect to (i) the $20 million development milestone received under the license agreement with Takeda in November 2026 and (ii) the Stock Repurchase, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into 2029.

Item 9.01     Financial Statements and Exhibits.
 
(d) Exhibits
Exhibit
No.Description
99.1
Press Release dated November 16, 2026.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
KEROS THERAPEUTICS, INC.
By:/s/ Jasbir Seehra
Jasbir Seehra, Ph.D.
Chief Executive Officer
Dated: November 16, 2026


Exhibit 99.1
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization

LEXINGTON, Mass., November 16, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a new $5 million share repurchase program of the Company’s common stock following receipt of a $20 million development milestone payment under the license agreement of elritercept with Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MF clinical trial. This approval grants Keros’ management the authority to repurchase outstanding shares of the Company’s common stock, from time to time, in the open market and/or by such other means in accordance with applicable state and federal securities laws.

The timing and amount of any repurchases will depend on a variety of factors, including the market price of the Company’s common stock, general market and economic conditions, contractual limitations and other considerations. The program may be modified, suspended or discontinued at any time, and does not obligate the Company to repurchase any dollar amount or number of shares.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “may,” “potential,” “will” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: the Company’s share repurchase program, including the timing, manner and amount of any repurchases; and Keros’ capital allocation strategy and plans for use of its capital resources. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: risks related to the Company’s ability to repurchase shares, including market conditions, stock price fluctuations, and regulatory and contractual constraints; Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.



These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 5, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Justin Frantz
jfrantz@kerostx.com
617-221-6042



Filing Exhibits & Attachments

4 documents

Keep reading